These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25732742)

  • 1. Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.
    Quatromoni N; Tuteja S; Kolanksy DM; Matthai WH; Giri J
    Curr Atheroscler Rep; 2015 May; 17(5):501. PubMed ID: 25732742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current evidence for monitoring platelet reactivity in acute coronary syndrome: a plea for individualized antiplatelet treatment.
    Aradi D; Sibbing D; Bonello L
    Int J Cardiol; 2013 Sep; 167(5):1794-7. PubMed ID: 23290951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
    Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
    Tsoumani ME; Tatsidou PT; Ntalas IV; Goudevenos JA; Tselepis AD
    Platelets; 2016 Dec; 27(8):812-820. PubMed ID: 27337147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
    Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
    PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
    Sinhal AR; Aylward PE
    Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
    Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T
    Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
    Bonhomme F; Bonvini R; Reny JL; Poncet A; Fontana P
    Platelets; 2015; 26(4):324-30. PubMed ID: 25905916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.